Vaginal Panel Testing Market Trends, 2021-2031

Vaginal Panel Testing Market (Type: Direct Molecular DNA Probe and Molecular Nucleic Acid Amplification Test [NAAT]; Application: Bacterial Vaginosis, Vulvovaginal Candidiasis, Chlamydia, Gonorrhoea, Trichomoniasis, and Others; and End-user: Hospitals, Diagnostic Centers, and Others) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Home Testing Paves Way for eCommerce Expansion Post Coronavirus Outbreak

The coronavirus outbreak has subsided significantly, as the end of 2021 is nearing. This outbreak led to several developments in the healthcare industry, especially in the vaginal panel testing market in EMEA. The trend of home testing has benefitted healthcare companies within the market landscape. This is why manufacturers are tapping revenue opportunities through eCommerce to expand their revenue streams.

Since manufacturers witnessed supply shortage for laboratory items during the peak pandemic period, companies in the vaginal panel testing market in EMEA are increasing efforts to maintain optimum inventory levels. Surge in spending capacity of individuals and relaxation of COVID-19 restrictions across countries is contributing toward the increase in overall revenue flow in the market.

emea vaginal panel testing market infographic

Request a sample to get extensive insights into the Vaginal Panel Testing Market

Next-gen Assays Help Fewer Recurrent Doctor Office Visits

Companies are increasing the production of molecular nucleic acid amplification tests (NAAT) to support the detection of vaginitis and vaginosis. The high prevalence of candida vaginitis, trichomoniasis, and bacterial vaginosis (BV) among women has led to innovations in assays. Manufacturers are increasing the availability of vaginitis panels that aid in the detection of yeast infections and trichomoniasis.

The vaginal panel testing market in EMEA is projected to cross US$ 175 Mn by 2031. Companies are increasing R&D in assays that enable better guided drug treatment, reduced suffering in affected women, and fewer recurrent doctor’s office visits. Such assays are helping healthcare companies to advance in molecular testing.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Innovations in Panels Help in Detection of Sexual and Vaginal Disease States

The vaginal panel testing market in EMEA is slated to clock a CAGR of 3.9% during the forecast period. Nevertheless, intensified competition in the market is challenging companies to develop an assay portfolio that caters to both sexual and vaginal health, which includes vaginitis testing alongside comprehensive sexually transmitted infections (STIs) and viral load testing.

There is a growing demand for vaginal panels that provide the flexibility to detect several infections and disease states with only one vaginal swab, which includes gonorrhea and candida species. Since the CDC (Centers for Disease Control and Prevention) is recommending the testing of trichomonas vaginalis (TV) in all women seeking treatment for vaginal discharge, such findings are leading to product sales.

At-home Vaginal Panel Testing Products Provide Privacy and Convenience to Women

Privacy and convenience are becoming important factors in the vaginal panel testing market in EMEA. This has led to innovations in affordable at-home testing products. Manufacturers in the vaginal panel testing market in EMEA are boosting the production of lab certified vaginal panels that help to generate results in less than five days. Since many women are concerned for unusual changes in the color, odor, and texture of vaginal discharge, at-home vaginal panel testing products are providing them several advantages.

At-home vaginal panel testing products eliminate the need of awkward conversations with peers and physicians, and help to screen common causes of abnormal vaginal discharge at comfort of the home.

FDA-authorized Products Enable Companies to Gain Competitive Edge

Molecular testing using a DNA probe for the detection of candida species and gardnerella vaginalis is growing prominent in the vaginal panel testing market in EMEA. Companies are increasing research in this space, since vaginitis accounts for several doctor office visits each year. Since the complications of BV can be significant in pregnant women, manufacturers are boosting output capacities in vaginal panel testing products.

In order to boost credibility, companies in the vaginal panel testing market in EMEA are increasing the availability of FDA-authorized products. These include polymerase chain reaction (PCR) assay and microbiome-based vaginal panel tests. Companies are innovating in assays that support antimicrobial resistance initiatives in women by detecting the presence of Candida krusei and C. glabrata.

emea vaginal panel testing market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on Vaginal Panel Testing Market

Analysts’ Viewpoint

Affordable at-home testing trends are creating revenue opportunities for companies in the vaginal panel testing market in EMEA in eCommerce during the post coronavirus period. Since traditional diagnostic techniques tend to be subjective with variable sensitivity and specificity, healthcare companies are capitalizing on this opportunity to innovate in vaginal panels. However, a negative test result done with vaginitis panel testing by DNA direct probe does not rule out the presence of microorganisms below the test sensitivity. Hence, companies should increase awareness about using vaginitis panel testing by DNA direct probe with vaginal specimens to improve medical outcomes. There is a growing demand for products that reduce repeated doctor visits and improve antimicrobial stewardship.

Europe and Middle East & Africa Vaginal Panel Testing Market: Overview

  • Vaginal panel testing is an automated qualitative in vitro diagnostic test for the direct detection of DNA targets from bacteria associated with bacterial vaginosis, candida species associated with vulvovaginal candidiasis, and trichomonas vaginalis
  • The test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA from
  • Vaginal panel assists in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis

Europe and Middle East & Africa Vaginal Panel Testing Market: Key Drivers

  • Accurate screening & detection of bacterial, yeast, fungi, and viral samples in clinical pathology using vaginal testing panels has allowed less turnaround time due to lower chances of producing false positive results because of their broad coverage of microbes of different classes, sensitivity, and effectiveness for the production of the results. This will help in more women undergoing diagnostic tests for vaginal testing, which, in turn, is likely to increase the number of diagnostic vaginal testing procedures.
  • Moreover, incidence of vaginal disorders is common among young women, and around 32% of the female population struggles with different kinds of vaginal complications. Most vaginal infections are asymptomatic and hence, it is difficult to predict the initial onset. Therefore, more women are likely to undergo molecular diagnostic tests for vaginal infections, which is projected drive the global vaginal testing panels market.

Market Segmentation: Europe and Middle East & Africa Vaginal Panel Testing Market

  • In terms of type, the vaginal panel testing market in EMEA has been bifurcated into direct molecular DNA probe and molecular nucleic acid amplification test (NAAT)
  • Based on application, the vaginal panel testing market in EMEA has been classified into bacterial vaginosis, vulvovaginal candidiasis, chlamydia, gonorrhoea, trichomoniasis, and others
  • In terms of end-user, the vaginal panel testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The vaginal panel testing market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Europe and Middle East & Africa Vaginal Panel Testing Market

  • Europe dominated the vaginal panel testing market in EMEA in 2020, accounting for 87.9% share. Increase in health awareness, rise in expenditure on healthcare infrastructure, and surge in demand for better healthcare facilities fuel the growth of the vaginal testing panels market in Europe.
  • Germany is projected to be an attractive market from 2021 to 2031. The country is anticipated to account for significant share of the market in Europe during the forecast period. Growth of the market in the country can be attributed to increase in research activities, rise in government funding for research & development, and surge in the number of biotechnology companies.

Major Players

  • The vaginal panel testing market report concludes with the company profiles section, which includes key information about major players in the vaginal panel testing market in EMEA
  • Leading players analyzed in the report include
    • Abbott Laboratories
    • Atrida
    • Becton
    • Dickenson and Company
    • Cepheid (Danaher Corporation)
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • Laboratory Corporation of America Holdings
    • Mologic Ltd.
    • QIAGEN
    • Quest Diagnostics Incorporated
    • Quidel Corporation
  • Each of these players has been profiled in the vaginal panel testing market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Europe and Middle East & Africa Vaginal Panel Testing Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 117.5 Mn

Market Forecast Value in 2031

US$ 175 Mn

Growth Rate (CAGR)

3.9%

Forecast Period

2021–2031

Historical Data Available for

2017–2019

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Direct Molecular DNA Probe
    • Molecular Nucleic Acid Amplification Test (NAAT)
  • Application
    • Bacterial Vaginosis
    • Vulvovaginal Candidiasis
    • Chlamydia
    • Gonorrhoea
    • Trichomoniasis
    • Others
  • End-user
    • Hospitals
    • Diagnostic Centers
    • Others

Regions Covered

  • Europe
  • Middle East & Africa

Countries Covered

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Finland
  • Austria
  • Switzerland
  • Benelux
  • Norway
  • Poland
  • Rest of Europe

Companies Profiled

  • Abbott Laboratories
  • Atrida
  • Becton, Dickenson and Company
  • Cepheid (Danaher Corporation)
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • Mologic Ltd.
  • QIAGEN
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Europe and Middle East & Africa Vaginal Panel Testing Market – Segmentation

TMR’s study on the vaginal panel testing market in EMEA includes information divided into four segments: type, application, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the vaginal panel testing market in EMEA are discussed in detail.

Type
  • Direct Molecular DNA Probe
  • Molecular Nucleic Acid Amplification Test (NAAT)
Application
  • Bacterial Vaginosis
  • Vulvovaginal Candidiasis
  • Chlamydia
  • Gonorrhoea
  • Trichomoniasis
  • Others
End-user
  • Hospitals
  • Diagnostic Centers
  • Others
Region
  • Europe
  • Middle East & Africa

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Europe and Middle East & Africa Vaginal Panel Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Key Industry Events (mergers, acquisitions, partnerships, etc.)

        5.2. Technological Advancements

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long-term impact)

    6. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Type, 2018–2030

            6.3.1. Direct Molecular DNA Probe

            6.3.2. Molecular Nucleic Acid Amplification Test (NAAT)

        6.4. Market Attractiveness Analysis, by Type

    7. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2018–2030

            7.3.1. Bacterial Vaginosis

            7.3.2. Vulvovaginal Candidiasis

            7.3.3. Chlamydia

            7.3.4. Gonorrhoea

            7.3.5. Trichomoniasis

            7.3.6. Others

        7.4. Market Attractiveness Analysis, by Application

    8. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2018–2030

            8.3.1. Hospitals

            8.3.2. Diagnostic Centers

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Europe and Middle East & Africa Vaginal Panel Testing Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. Europe

            9.2.2. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. Europe Vaginal Panel Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Type, 2018–2030

            10.2.1. Direct molecular Direct Molecular DNA Probe

            10.2.2. Molecular Nucleic Acid Amplification Test (NAAT)

        10.3. Market Value Forecast, by Application, 2018–2030

            10.3.1. Bacterial Vaginosis

            10.3.2. Vulvovaginal Candidiasis

            10.3.3. Chlamydia

            10.3.4. Gonorrhoea

            10.3.5. Trichomoniasis

            10.3.6. Others

        10.4. Market Value Forecast, by End-user, 2018–2030

            10.4.1. Hospitals

            10.4.2. Diagnostic Centers

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2018–2030

            10.5.1. Germany

                10.5.1.1. Market Value Forecast, by Type, 2017–2031

                    10.5.1.1.1. Polymerase Chain Reaction (PCR) Assay

                    10.5.1.1.2. Direct Molecular DNA Probe

                    10.5.1.1.3. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.1.2. Market Value Forecast, by Application, 2017–2031

                    10.5.1.2.1. Bacterial Vaginosis

                    10.5.1.2.2. Vulvovaginal Candidiasis

                    10.5.1.2.3. Chlamydia

                    10.5.1.2.4. Gonorrhoea

                    10.5.1.2.5. Trichomoniasis

                    10.5.1.2.6. Others

                10.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.1.3.1. Hospital

                    10.5.1.3.2. Diagnostic Centers

                    10.5.1.3.3. Others

            10.5.2. U.K.

                10.5.2.1. Market Value Forecast, by Type, 2017–2031

                    10.5.2.1.1. Polymerase Chain Reaction (PCR) Assay

                    10.5.2.1.2. Direct Molecular DNA Probe

                    10.5.2.1.3. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.2.2. Market Value Forecast, by Application, 2017–2031

                    10.5.2.2.1. Bacterial Vaginosis

                    10.5.2.2.2. Vulvovaginal Candidiasis

                    10.5.2.2.3. Chlamydia

                    10.5.2.2.4. Gonorrhoea

                    10.5.2.2.5. Trichomoniasis

                    10.5.2.2.6. Others

                10.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.2.3.1. Hospital

                    10.5.2.3.2. Diagnostic Centers

                    10.5.2.3.3. Others

            10.5.3. France

                10.5.3.1. Market Value Forecast, by Type, 2017–2031

                    10.5.3.1.1. Direct Molecular DNA Probe

                    10.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.3.2. Market Value Forecast, by Application, 2017–2031

                    10.5.3.2.1. Bacterial Vaginosis

                    10.5.3.2.2. Vulvovaginal Candidiasis

                    10.5.3.2.3. Chlamydia

                    10.5.3.2.4. Gonorrhoea

                    10.5.3.2.5. Trichomoniasis

                    10.5.3.2.6. Others

                10.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.3.3.1. Hospital

                    10.5.3.3.2. Diagnostic Centers

                    10.5.3.3.3. Others

            10.5.4. Italy

                10.5.4.1. Market Value Forecast, by Type, 2017–2031

                    10.5.4.1.1. Direct Molecular DNA Probe

                    10.5.4.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.4.2. Market Value Forecast, by Application, 2017–2031

                    10.5.4.2.1. Bacterial Vaginosis

                    10.5.4.2.2. Vulvovaginal Candidiasis

                    10.5.4.2.3. Chlamydia

                    10.5.4.2.4. Gonorrhoea

                    10.5.4.2.5. Trichomoniasis

                    10.5.4.2.6. Others

                10.5.4.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.4.3.1. Hospital

                    10.5.4.3.2. Diagnostic Centers

                    10.5.4.3.3. Others

            10.5.5. Spain

                10.5.5.1. Market Value Forecast, by Type, 2017–2031

                    10.5.5.1.1. Direct Molecular DNA Probe

                    10.5.5.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.5.2. Market Value Forecast, by Application, 2017–2031

                    10.5.5.2.1. Bacterial Vaginosis

                    10.5.5.2.2. Vulvovaginal Candidiasis

                    10.5.5.2.3. Chlamydia

                    10.5.5.2.4. Gonorrhoea

                    10.5.5.2.5. Trichomoniasis

                    10.5.5.2.6. Others

                10.5.5.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.5.3.1. Hospital

                    10.5.5.3.2. Diagnostic Centers

                    10.5.5.3.3. Others

            10.5.6. Sweden

                10.5.6.1. Market Value Forecast, by Type, 2017–2031

                    10.5.6.1.1. Direct Molecular DNA Probe

                    10.5.6.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.6.2. Market Value Forecast, by Application, 2017–2031

                    10.5.6.2.1. Bacterial Vaginosis

                    10.5.6.2.2. Vulvovaginal Candidiasis

                    10.5.6.2.3. Chlamydia

                    10.5.6.2.4. Gonorrhoea

                    10.5.6.2.5. Trichomoniasis

                    10.5.6.2.6. Others

                10.5.6.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.6.3.1. Hospital

                    10.5.6.3.2. Diagnostic Centers

                    10.5.6.3.3. Others

            10.5.7. Denmark

                10.5.7.1. Market Value Forecast, by Type, 2017–2031

                    10.5.7.1.1. Direct Molecular DNA Probe

                    10.5.7.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.7.2. Market Value Forecast, by Application, 2017–2031

                    10.5.7.2.1. Bacterial Vaginosis

                    10.5.7.2.2. Vulvovaginal Candidiasis

                    10.5.7.2.3. Chlamydia

                    10.5.7.2.4. Gonorrhoea

                    10.5.7.2.5. Trichomoniasis

                    10.5.7.2.6. Others

                10.5.7.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.7.3.1. Hospital

                    10.5.7.3.2. Diagnostic Centers

                    10.5.7.3.3. Others

            10.5.8. Finland

                10.5.8.1. Market Value Forecast, by Type, 2017–2031

                    10.5.8.1.1. Direct Molecular DNA Probe

                    10.5.8.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.8.2. Market Value Forecast, by Application, 2017–2031

                    10.5.8.2.1. Bacterial Vaginosis

                    10.5.8.2.2. Vulvovaginal Candidiasis

                    10.5.8.2.3. Chlamydia

                    10.5.8.2.4. Gonorrhoea

                    10.5.8.2.5. Trichomoniasis

                    10.5.8.2.6. Others

                10.5.8.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.8.3.1. Hospital

                    10.5.8.3.2. Diagnostic Centers

                    10.5.8.3.3. Others

            10.5.9. Austria

                10.5.9.1. Market Value Forecast, by Type, 2017–2031

                    10.5.9.1.1. Direct Molecular DNA Probe

                    10.5.9.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.9.2. Market Value Forecast, by Application, 2017–2031

                    10.5.9.2.1. Bacterial Vaginosis

                    10.5.9.2.2. Vulvovaginal Candidiasis

                    10.5.9.2.3. Chlamydia

                    10.5.9.2.4. Gonorrhoea

                    10.5.9.2.5. Trichomoniasis

                    10.5.9.2.6. Others

                10.5.9.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.9.3.1. Hospital

                    10.5.9.3.2. Diagnostic Centers

                    10.5.9.3.3. Others

            10.5.10. Switzerland

                10.5.10.1. Market Value Forecast, by Type, 2017–2031

                    10.5.10.1.1. Direct Molecular DNA Probe

                    10.5.10.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.10.2. Market Value Forecast, by Application, 2017–2031

                    10.5.10.2.1. Bacterial Vaginosis

                    10.5.10.2.2. Vulvovaginal Candidiasis

                    10.5.10.2.3. Chlamydia

                    10.5.10.2.4. Gonorrhoea

                    10.5.10.2.5. Trichomoniasis

                    10.5.10.2.6. Others

                10.5.10.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.10.3.1. Hospital

                    10.5.10.3.2. Diagnostic Centers

                    10.5.10.3.3. Others

            10.5.11. Benelux

                10.5.11.1. Market Value Forecast, by Type, 2017–2031

                    10.5.11.1.1. Direct Molecular DNA Probe

                    10.5.11.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.11.2. Market Value Forecast, by Application, 2017–2031

                    10.5.11.2.1. Bacterial Vaginosis

                    10.5.11.2.2. Vulvovaginal Candidiasis

                    10.5.11.2.3. Chlamydia

                    10.5.11.2.4. Gonorrhoea

                    10.5.11.2.5. Trichomoniasis

                    10.5.11.2.6. Others

                10.5.11.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.11.3.1. Hospital

                    10.5.11.3.2. Diagnostic Centers

                    10.5.11.3.3. Others

            10.5.12. Norway

                10.5.12.1. Market Value Forecast, by Type, 2017–2031

                    10.5.12.1.1. Direct Molecular DNA Probe

                    10.5.12.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.12.2. Market Value Forecast, by Application, 2017–2031

                    10.5.12.2.1. Bacterial Vaginosis

                    10.5.12.2.2. Vulvovaginal Candidiasis

                    10.5.12.2.3. Chlamydia

                    10.5.12.2.4. Gonorrhoea

                    10.5.12.2.5. Trichomoniasis

                    10.5.12.2.6. Others

                10.5.12.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.12.3.1. Hospital

                    10.5.12.3.2. Diagnostic Centers

                    10.5.12.3.3. Others

            10.5.13. Poland

                10.5.13.1. Market Value Forecast, by Type, 2017–2031

                    10.5.13.1.1. Direct Molecular DNA Probe

                    10.5.13.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.13.2. Market Value Forecast, by Application, 2017–2031

                    10.5.13.2.1. Bacterial Vaginosis

                    10.5.13.2.2. Vulvovaginal Candidiasis

                    10.5.13.2.3. Chlamydia

                    10.5.13.2.4. Gonorrhoea

                    10.5.13.2.5. Trichomoniasis

                    10.5.13.2.6. Others

                10.5.13.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.13.3.1. Hospital

                    10.5.13.3.2. Diagnostic Centers

                    10.5.13.3.3. Others

            10.5.14. Rest of Europe

                10.5.14.1. Market Value Forecast, by Type, 2017–2031

                    10.5.14.1.1. Direct Molecular DNA Probe

                    10.5.14.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                10.5.14.2. Market Value Forecast, by Application, 2017–2031

                    10.5.14.2.1. Bacterial Vaginosis

                    10.5.14.2.2. Vulvovaginal Candidiasis

                    10.5.14.2.3. Chlamydia

                    10.5.14.2.4. Gonorrhoea

                    10.5.14.2.5. Trichomoniasis

                    10.5.14.2.6. Others

                10.5.14.3. Market Value Forecast, by End-user, 2017–2031

                    10.5.14.3.1. Hospital

                    10.5.14.3.2. Diagnostic Centers

                    10.5.14.3.3. Others

        10.6. Market Attractiveness Analysis

            10.6.1. By Type

            10.6.2. By Application

            10.6.3. By End-user

            10.6.4. By Country

    11. Middle East & Africa Vaginal Testing Panels Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Type, 2017–2031

            11.2.1. Direct Molecular DNA Probe

            11.2.2. Molecular Nucleic Acid Amplification Test (NAAT)

        11.3. Market Value Forecast, by Application, 2017–2031

            11.3.1. Bacterial Vaginosis

            11.3.2. Vulvovaginal Candidiasis

            11.3.3. Chlamydia

            11.3.4. Gonorrhoea

            11.3.5. Trichomoniasis

            11.3.6. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospital

            11.4.2. Diagnostic Centers

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. GCC Countries

                11.5.1.1. Market Value Forecast, by Type, 2017–2031

                    11.5.1.1.1. Direct Molecular DNA Probe

                    11.5.1.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                11.5.1.2. Market Value Forecast, by Application, 2017–2031

                    11.5.1.2.1. Bacterial Vaginosis

                    11.5.1.2.2. Vulvovaginal Candidiasis

                    11.5.1.2.3. Chlamydia

                    11.5.1.2.4. Gonorrhoea

                    11.5.1.2.5. Trichomoniasis

                    11.5.1.2.6. Others

                11.5.1.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.1.3.1. Hospital

                    11.5.1.3.2. Diagnostic Centers

                    11.5.1.3.3. Others

            11.5.2. South Africa

                11.5.2.1. Market Value Forecast, by Type, 2017–2031

                    11.5.2.1.1. Direct Molecular DNA Probe

                    11.5.2.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                11.5.2.2. Market Value Forecast, by Application, 2017–2031

                    11.5.2.2.1. Bacterial Vaginosis

                    11.5.2.2.2. Vulvovaginal Candidiasis

                    11.5.2.2.3. Chlamydia

                    11.5.2.2.4. Gonorrhoea

                    11.5.2.2.5. Trichomoniasis

                    11.5.2.2.6. Others

                11.5.2.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.2.3.1. Hospital

                    11.5.2.3.2. Diagnostic Centers

                    11.5.2.3.3. Others

            11.5.3. Rest of Middle East & Africa

                11.5.3.1. Market Value Forecast, by Type, 2017–2031

                    11.5.3.1.1. Direct Molecular DNA Probe

                    11.5.3.1.2. Molecular Nucleic Acid Amplification Test (NAAT)

                11.5.3.2. Market Value Forecast, By Application, 2017–2031

                    11.5.3.2.1. Bacterial Vaginosis

                    11.5.3.2.2. Vulvovaginal Candidiasis

                    11.5.3.2.3. Chlamydia

                    11.5.3.2.4. Gonorrhoea

                    11.5.3.2.5. Trichomoniasis

                    11.5.3.2.6. Others

                11.5.3.3. Market Value Forecast, by End-user, 2017–2031

                    11.5.3.3.1. Hospital

                    11.5.3.3.2. Diagnostic Centers

                    11.5.3.3.3. Others

        11.6. Market Attractiveness Analysis

            11.6.1. By Type

            11.6.2. By Application

            11.6.3. By End-user

            11.6.4. By Country

    12. Competition Landscape

        12.1. Market Player - Competition Matrix (by tier and size of companies)

        12.2. Company Profiles

            12.2.1. Becton Dickenson

                12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.1.2. Product Portfolio

                12.2.1.3. SWOT Analysis

                12.2.1.4. Strategic Overview

            12.2.2. Atrida

                12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.2.2. Product Portfolio

                12.2.2.3. SWOT Analysis

                12.2.2.4. Strategic Overview

            12.2.3. Hologic, Inc.

                12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.3.2. Product Portfolio

                12.2.3.3. SWOT Analysis

                12.2.3.4. Strategic Overview

            12.2.4. Quest Diagnostics Incorporated

                12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.4.2. Product Portfolio

                12.2.4.3. SWOT Analysis

                12.2.4.4. Strategic Overview

            12.2.5. Quidel Corporation

                12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.5.2. Product Portfolio

                12.2.5.3. SWOT Analysis

                12.2.5.4. Strategic Overview

            12.2.6. Mologic Ltd.

                12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.6.2. Product Portfolio

                12.2.6.3. SWOT Analysis

                12.2.6.4. Strategic Overview

            12.2.7. F. Hoffmann-La Roche Ltd.

                12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.7.2. Product Portfolio

                12.2.7.3. SWOT Analysis

                12.2.7.4. Strategic Overview

            12.2.8. QIAGEN

                12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.8.2. Product Portfolio

                12.2.8.3. SWOT Analysis

                12.2.8.4. Strategic Overview

            12.2.9. Abbott Laboratories

                12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.9.2. Product Portfolio

                12.2.9.3. SWOT Analysis

                12.2.9.4. Strategic Overview

            12.2.10. Cepheid (Danaher Corporation)

                12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.10.2. Product Portfolio

                12.2.10.3. SWOT Analysis

                12.2.10.4. Strategic Overview

            12.2.11. Laboratory Corporation of America Holdings

                12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                12.2.11.2. Product Portfolio

                12.2.11.3. SWOT Analysis

                12.2.11.4. Strategic Overview

    List of Table

    Table 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 02: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 03: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 06: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 07: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 08: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 09: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 10: Germany Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 11: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 12: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 13: U.K. Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 14: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 15: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 16: France Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 17: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 18: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 19: Italy Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 20: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 21: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 22: Spain Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 23: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 24: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 25: Sweden Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 26: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 27: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 28: Denmark Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 29: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 30: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 31: Finland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 32: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 33: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 34: Austria Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 35: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 36: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 37: Switzerland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 38: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 39: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 40: Benelux Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 41: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 42: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 43: Norway Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 44: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 45: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 46: Poland Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 47: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 48: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 49: Rest of Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 50: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 51: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 52: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 53: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 54: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 55: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 56: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 57: GCC Countries Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 58: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 59: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 60: South Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 61: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by Type, 2017–2031

    Table 62: Rest of Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figure

    Figure 01: EMEA Vaginal Panel Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: EMEA Vaginal Panel Testing Market Value Share, by Application, 2020

    Figure 03: EMEA Vaginal Panel Testing Market Value Share, by Type, 2020

    Figure 04: EMEA Vaginal Panel Testing Market Value Share, by End-user, 2020

    Figure 05: EMEA Vaginal Panel Testing Market Value Share, by Region, 2020

    Figure 06: EMEA Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 07: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 08: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Direct Molecular DNA Probe, 2017–2031

    Figure 09: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Molecular Nucleic Acid Amplification Test (NAAT), 2017–2031

    Figure 10: EMEA Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 11: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 12: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Bacterial Vaginosis, 2017–2031

    Figure 13: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Vulvovaginal Candidiasis, 2017–2031

    Figure 14: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Chlamydia, 2017–2031

    Figure 15: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Gonorrhoea, 2017–2031

    Figure 16: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Trichomoniasis, 2017–2031

    Figure 17: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

    Figure 18: EMEA Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 19: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 19: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

    Figure 20: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031

    Figure 21: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Diagnostic Centers, 2017–2031

    Figure 22: EMEA Vaginal Panel Testing Market Value (US$ Mn), by Others, 2017–2031

    Figure 23: EMEA Vaginal Panel Testing Market Analysis, 2020 and 2031

    Figure 24: EMEA Vaginal Panel Testing Market Attractiveness Analysis, by Region, 2021–2031

    Figure 25: Europe Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 26: Europe Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

    Figure 27: Europe Vaginal Panel Testing Market Attractiveness Analysis by Country/Sub-region, 2021–2031

    Figure 28: Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 29: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 30: Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 31: Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 32: Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 33: Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 34: Germany Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 35: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 36: Germany Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 37: Germany Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 38: Germany Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 39: Germany Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 40: U.K. Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 41: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 42: U.K. Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 43: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 44: U.K. Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 45: U.K. Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 46: France Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 47: France Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 48: France Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 49: France Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 50: France Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 51: France Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 52: Italy Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 53: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 54: Italy Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 55: Italy Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 56: Italy Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 57: Italy Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 58: Spain Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 59: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 60: Spain Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 61: Spain Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 62: Spain Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 63: Spain Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 64: Sweden Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 65: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 66: Sweden Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 67: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 68: Sweden Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 69: Sweden Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 70: Denmark Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 71: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 72: Denmark Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 73: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 74: Denmark Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 75: Breakdown of Net Sales (%), by Business Segment, 2020

    Figure 75: Denmark Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 76: Breakdown of Net Sales (%), by Region, 2020

    Figure 76: Finland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 77: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 78: Finland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 79: Finland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 80: Finland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 81: Finland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 82: Austria Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 83: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 84: Austria Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 85: Austria Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 86: Austria Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 87: Austria Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 88: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 89: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 90: Switzerland Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 91: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 92: Switzerland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 93: Switzerland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 94: Benelux Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 95: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 96: Benelux Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 97: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 98: Benelux Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 99: Benelux Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 100: Norway Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 101: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 102: Norway Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 103: Norway Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 104: Norway Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 105: Norway Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 106: Poland Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 107: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 108: Poland Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 109: Poland Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 110: Poland Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 111: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 112: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 113: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 114: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 115: Rest of Europe Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 116: Rest of Europe Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 117: Middle East & Africa Vaginal Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 118: Middle East & Africa Vaginal Panel Testing Market Value Share, by Country/Sub-region, 2020–2031

    Figure 119: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

    Figure 120: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 121: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 122: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 123: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 124: Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 125: Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 126: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 127: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 128: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 129: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 130: GCC Countries Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 131: GCC Countries Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 132: South Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 133: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 134: South Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 135: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 136: South Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 137: South Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 138: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Type, 2020 and 2031

    Figure 139: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Type, 2021–2031

    Figure 140: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by Application, 2020 and 2031

    Figure 141: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by Application, 2021–2031

    Figure 142: Rest of Middle East & Africa Vaginal Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031

    Figure 143: Rest of Middle East & Africa Vaginal Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031

    Figure 144: Vaginal Testing Panels Market Share, by Company, 2020

Copyright © Transparency Market Research, Inc. All Rights reserved